A pair of Bay State regenerative medicine firms, Histogenics Corp. and ProChon Biotech Ltd., merged in an all-stock deal that brings ProChon CEO Patrick O’Donnell into the Histogenics corner office.
O’Donnell told MassDevice.com that a deal has been in the works since the early part of 2011.